Summary
Eli Lilly & Company (LLY) filed a Form 8-K on October 29, 2025, to announce its financial results for the third quarter ended September 30, 2025. The filing incorporates by reference a press release, dated October 30, 2025, which contains the detailed financial performance for the period. While the 8-K itself is brief, the attached press release (Exhibit 99.1) is expected to provide investors with crucial insights into the company's revenue, earnings per share, product sales performance, and potentially guidance for the remainder of the fiscal year.
Key Highlights
- 1Form 8-K filed on October 29, 2025, announcing Q3 2025 financial results.
- 2Financial results for the quarter ended September 30, 2025, are detailed in an attached press release (Exhibit 99.1).
- 3The press release is expected to cover key operational and financial metrics.
- 4Investor focus will likely be on revenue growth, profitability, and specific drug performance mentioned in the press release.
- 5Guidance for future financial periods may be provided in the accompanying press release.
- 6This filing is primarily an announcement mechanism for the press release containing the core financial information.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce Eli Lilly & Company's financial results for the third quarter ended September 30, 2025. It incorporates a press release that contains the detailed financial performance and operational updates for the period.
The detailed financial results are provided in Exhibit 99.1, which is a press release dated October 30, 2025, attached to and incorporated by reference into this 8-K filing.
While the 8-K itself does not contain guidance, the accompanying press release (Exhibit 99.1) is expected to include financial guidance for future periods, which is standard practice for quarterly earnings announcements.
The information in Item 2.02, including the press release, is being furnished and is not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning the company generally has fewer liabilities associated with its accuracy unless otherwise stated.